| oxaliplatin / Generic mfg. |
NCT00003287: Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 554 | Canada, Europe | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | European Organisation for Research and Treatment of Cancer - EORTC | Colorectal Cancer | 03/02 | | | |
MOSAIC, NCT00275210: - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer |
|
|
| Completed | 3 | 2246 | Europe, RoW | Oxaliplatin (SR96669) | Sanofi | Colonic Neoplasms | 04/03 | 04/03 | | |
NCT00008060: Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer |
|
|
| Completed | 3 | | Europe | FOLFIRI regimen, FOLFOX regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Medical Research Council | Colorectal Cancer | | 12/03 | | |
NCT00202774: Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 348 | Europe | (capecitabine, oxaliplatin, 5-fluorouracil) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Colorectal Cancer | 08/04 | 12/05 | | |
NCT00061815: Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer |
|
|
| Completed | 3 | 102 | US | cetuximab, Erbitux™, oxaliplatin, Eloxatin®, leucovorin, Wellcovorin®, 5-fluorouracil, 5-FU | Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Cancer | 12/04 | 11/05 | | |
NSABP-C-07, NCT00004931: Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer |
|
|
| Completed | 3 | 2472 | US | leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, laboratory biomarker analysis | National Cancer Institute (NCI) | Stage II Colon Cancer, Stage III Colon Cancer | 09/05 | | | |
NCT01219920: FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 244 | Europe | FOLFIRI, Campto, l-lederfolin, 5-FU, FOLFOXIRI, Eloxatin, l-leucovorin, 5FU | Gruppo Oncologico del Nord-Ovest | Metastatic Colorectal Cancer | 11/05 | 11/09 | | |
NO16966, NCT00069095: A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 2035 | US, Canada, Europe, RoW | Oxaliplatin 130 mg/m^2, Eloxatin, Capecitabine 1000 mg/m^2, Xeloda, Bevacizumab 7.5 mg/kg, Avastin, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Efudex, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg | Hoffmann-La Roche | Colorectal Cancer | 01/06 | 04/09 | | |
NCT00312000: Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma |
|
|
| Completed | 3 | 820 | Europe | capecitabine-irinotecan, capecitabine+irinotecan (1st line) | Dutch Colorectal Cancer Group, Koningin Wilhelmina Fonds, Sanofi, Hoffmann-La Roche | Advanced Colorectal Cancer | 02/06 | 12/06 | | |
| Completed | 3 | 627 | US, Canada, Europe, RoW | 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda] | Hoffmann-La Roche | Colorectal Cancer | 08/06 | 08/06 | | |
SWOG-N9841, NCT00005036: Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | 560 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, quality-of-life assessment, quality of life assessment | National Cancer Institute (NCI), Southwest Oncology Group, Eastern Cooperative Oncology Group | Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 12/06 | | | |
NCT00077233: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum |
|
|
| Terminated | 3 | 238 | US | cetuximab, C225, 5-FU, 5-fluorouracil, irinotecan, CPT-11, leucovorin, calcium folinate, oxaliplatin, Eloxatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Bristol-Myers Squibb, Eli Lilly and Company | Colorectal Cancer | 12/06 | 06/10 | | |
|
|
NCT00056446: Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 855 | US, Canada, Europe, RoW | Vatalanib, PTK787/ZK 222584 | Novartis Pharmaceuticals, Bayer | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms | 01/07 | 01/07 | | |
|
NCT00070122: Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer |
|
|
| Terminated | 3 | 2200 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, capecitabine, CAPE, Ro 09-1978/000, Xeloda, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 01/07 | | | |
NCT00025337: Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated |
|
|
| Completed | 3 | 880 | US | bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 04/07 | | | |
NCT00115765: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study |
|
|
| Completed | 3 | 1053 | NA | Oxaliplatin Based Chemotherapy, FOLFOX 4, FOLFOX 5, Modified FOLFOX 6, FOLFOX 7, Oxaliplatin, Panitumumab, pmab, Vectibix, Irinotecan Based Chemotherapy, FOLFIRI, Douillard, Bevacizumab, Avastin | Amgen | Colorectal Cancer | 05/07 | 05/09 | | |
NCT00252564: Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 247 | US | Bevacizumab, Avastin, Oxaliplatin, Eloxatin, Leucovorin, Fluorouracil, 5FU, Cetuximab, Erbitux | US Oncology Research, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center, Prologue Research International | Metastatic Colorectal Cancer | 06/07 | 06/09 | | |
NCT00316914: Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery |
|
|
| Completed | 3 | 104 | US | calcium gluconate, magnesium sulfate, placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), North Central Cancer Treatment Group | Colorectal Cancer, Neurotoxicity | 01/08 | 11/12 | | |
CHRONICLE, NCT00427713: Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer |
|
|
| Completed | 3 | 800 | Europe | capecitabine, oxaliplatin, adjuvant therapy, standard follow-up care | Cancer Research UK | Colorectal Cancer | 03/08 | | | |
NCT00268463: Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer |
|
|
| Terminated | 3 | 22 | US | capecitabine, Xeloda, floxuridine, FUDR, oxaliplatin, Eloxatin | NSABP Foundation Inc, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 06/08 | 06/08 | | |
NCT00012389: Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | | US, Canada, Europe, RoW | irinotecan hydrochloride, oxaliplatin | Sanofi | Colorectal Cancer | | 10/08 | | |
NCT00349336: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 3 | 64 | Canada, RoW | bevacizumab [Avastin], XELOX, FOLFOX-4 | Hoffmann-La Roche | Colorectal Cancer | 11/08 | 11/08 | | |
NCT00316745: IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer |
|
|
| Suspended | 3 | 200 | Japan | Campto, Topotesin, Irinotecan, TS-1, S-1, L-Plat, Oxaliplatin, Isovorin, l-leucovorin, 5-FU, Fluorouracil | Hokkaido Gastrointestinal Cancer Study Group, Hokkaido University Hospital | Metastatic Colorectal Cancer | | 03/09 | | |
| Completed | 3 | 571 | Europe | FLOX (5-fluorouracil/folinic acid/oxaliplatin), FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab, FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab | The Nordic Colorectal Cancer Biomodulation Group | Metastatic Colorectal Cancer | 05/09 | 08/10 | | |
|
|
|
|
|
|
NCT00208546: Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer |
|
|
| Completed | 3 | 750 | Europe | 21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Dutch Colorectal Cancer Group, Koningin Wilhelmina Fonds, Sanofi, Roche Pharma AG, Immunicon | Colorectal Cancer | 07/09 | 12/09 | | |
|
|
|
|
NCT00677443: Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | 344 | RoW | S-1 & Oxaliplatin, S-1 and Oxaliplatin, Capecitabine & Oxaliplatin, Capecitabine and Oxaliplatin | Samsung Medical Center, National Cancer Center, Korea, Seoul National University Bundang Hospital, Seoul National University Hospital, Gachon University Gil Medical Center, Yonsei University, Asan Medical Center, Chonnam National University Hospital | Colorectal Cancer | 09/09 | 01/11 | | |
NCT00305188 / 2005-002570-30: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. |
|
|
| Completed | 3 | 879 | US, Canada, Europe, RoW | Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, 5-FU, Leucovorin, LV | Sanofi | Metastases, Colorectal Neoplasms, Colorectal Carcinoma | 10/09 | 10/09 | | |
| Completed | 3 | 249 | Europe | erlotinib (Tarceva), bevacizumab (Avastin) | Lund University Hospital, Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
|
|
|
|
|
XENON, NCT00603577 / 2007-000945-36: Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens |
|
|
| Terminated | 3 | 102 | US, Canada, Europe | Placebo, Xaliproden | Sanofi | Colorectal Neoplasms | 11/09 | 11/09 | | |
| Completed | 3 | 1254 | Europe, RoW | Cediranib, AZD2171, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Other Names:, 5-FU, Drug: Leucovorin (in FOLFOX), intravenous infusion, Drug: Oxaliplatin (in FOLFOX), Eloxatin®, XELOX (Capecitabine and Oxaliplatin), Xeloda® + Eloxatin®, Cediranib Placebo | AstraZeneca | Metastatic Colorectal Cancer | 03/10 | 08/16 | | |
|
|
|
|
AVANT, NCT00112918: Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer |
|
|
| Completed | 3 | 3451 | US | Bevacizumab, Capecitabine, Xeloda®, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin | Hoffmann-La Roche, National Cancer Institute (NCI) | Colorectal Cancer | 06/10 | 06/12 | | |
|
NCT00062426: Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | | US | bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | | 02/11 | | |
VELOUR, NCT00561470 / 2007-000820-42: Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen |
|
|
| Completed | 3 | 1226 | US, Europe, RoW | Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Sanofi, Regeneron Pharmaceuticals, NSABP Foundation Inc | Colorectal Neoplasms, Neoplasm Metastasis | 02/11 | 06/12 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00440310 / 2006-004214-41: Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases |
|
|
| Completed | 3 | 483 | Europe, RoW | Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes, FOLFOX4 regimen, FOLFIRI regimen | Light Sciences Oncology | Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local | 05/11 | 10/11 | | |
| Completed | 3 | 509 | Europe | bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer | 05/11 | | | |
|
|
|
|
|
|
|
|
|
|
|
|
PETACC-6, NCT00766155 / 2006-006532-21: Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | 3 | 1094 | US | capecitabine, oxaliplatin | European Organisation for Research and Treatment of Cancer - EORTC | Colorectal Cancer | 09/11 | | | |
MIROX, NCT00268398: Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases |
|
|
| Completed | 3 | 284 | Europe | oxaliplatin, folinic acid, fluorouracil, oxaliplatin, irinotecan, folinic acid, fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer, Metastatic Cancer, Chemotherapy | 12/11 | | | |
NCT01189227: Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery |
|
|
| Terminated | 3 | 9 | US | Postoperative chemotherapy, Perioperative chemotherapy | NSABP Foundation Inc, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 12/11 | 12/11 | | |
NCT00623805: A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 123 | RoW | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Hoffmann-La Roche | Colorectal Cancer | 05/12 | 05/12 | | |
|
NCT00335595 / 2005-003325-67: Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients |
|
|
| Completed | 3 | 480 | Europe | XELOXA, XELOXA-A | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi, Roche Pharma AG | Colorectal Cancer | 06/12 | 06/12 | | |
|
| Completed | 3 | 847 | US, Canada, Europe, RoW | Pegfilgrastim, Neulasta®, Placebo, Bevacizumab, Avastin®, Standard Chemotherapy | Amgen | Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer | 09/12 | 01/15 | | |
|
|
SWOG-S0600, NCT00499369: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy |
|
|
| Terminated | 3 | 72 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF | National Cancer Institute (NCI), North Central Cancer Treatment Group, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, NCIC Clinical Trials Group | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 11/12 | 11/12 | | |
BEBYP, NCT00720512 / 2007-002886-11: Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab |
|
|
| Terminated | 3 | 184 | Europe | bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer | 02/13 | 03/14 | | |
|
|
|
| Completed | 3 | 200 | Canada | Glutamine, Calcium and Magnesium | Sanofi | Colorectal Neoplasms | 03/13 | 03/13 | | |
| Completed | 3 | 3756 | Europe | FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin), FOLFOX 3 vs 6 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Mario Negri Institute for Pharmacological Research | Colon Cancer | 04/13 | 11/14 | | |
| Completed | 3 | 820 | Europe, RoW | Chemotherapy, Bevacizumab, Avastin | Hoffmann-La Roche | Colorectal Cancer | 05/13 | 05/13 | | |
|
|
|
|
|
|
|
|
| Terminated | 3 | 79 | Europe | oxaliplatin+capecitabine, Oxaliplatin+capecitabine+bevacizumab | Dutch Colorectal Cancer Group, Sanofi, Roche Pharma AG | Colorectal Cancer, Liver Metastases | 08/13 | 08/13 | | |
|
| Completed | 3 | 350 | Europe | Arm A: FOLFIRI or FOLFOX + Bevacizumab, Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB, Arm B: FOLFIRI or FOLFOX, Arm C: FOLFIRI or FOLFOX, Arm D: FOLFIRI or FOLFOX plus CETUXIMAB, FOLFIRI or FOLFOX plus CETUXIMAB, Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB, FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Metastatic Colorectal Cancer | 03/14 | 03/18 | | |
|
|
|
|
NCT01080547: Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer |
|
|
| Completed | 3 | 374 | RoW | Laparoscopic Surgery for Colorectal Cancer, STORZ laparoscope, XELOX Chemotherapy, Capecitabine, Oxaliplatin, mFolfox6 chemotherapy, Fast Track Perioperative Treatment, Fast track surgery, Conventional Perioperative Treatment, Traditional Perioperative Treatment, Open Surgery for Colorectal Cancer, Traditional open surgery | Zhejiang University | Length of Stay, Complications, Adverse Drug Event, Quality of Life, Hospital Costs | 04/14 | 12/14 | | |
NCT02060669: Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer |
|
|
| Terminated | 3 | 10 | RoW | Xeloda | Samsung Medical Center, Roche Pharma AG | Metastatic Colorectal Cancer | 05/14 | 09/14 | | |
AFLAME, NCT01661270: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy |
|
|
| Completed | 3 | 332 | Japan, RoW | Aflibercept, AVE0005, Zaltrap, Placebo | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 10/14 | 07/15 | | |
NCT01279681: Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 3 | 32 | NA | bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Cancer and Leukemia Group B | Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity | 11/14 | 11/14 | | |
|
| Completed | 3 | 853 | Europe | 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab | AIO-Studien-gGmbH, Roche Pharma AG | Colorectal Neoplasms | 12/14 | 08/15 | | |
|
|
|
| Completed | 3 | 110 | Europe | FOLFOX-4, Oxaliplatin, 5FU, Leucovorin, Irinotecan/Cetuximab, CPT11/Cetuximab | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Metastatic Colorectal Cancer | 04/15 | 06/15 | | |
|
|
|
|
NCT01338558: A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab |
|
|
| Withdrawn | 3 | 0 | Europe | bevacizumab [Avastin], cetuximab, mFOLFOX6 | Hoffmann-La Roche | Colorectal Cancer | 05/15 | 05/15 | | |
| Completed | 3 | 175 | Europe | AFLIBERCEPT, AVE0005, Irinotecan, Fluorouracil, Leucovorin | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 06/15 | 06/15 | | |
|
|
NCT00349076 / 2006-002385-20: Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer |
|
|
| Completed | 3 | 1256 | Europe | 5-FU and oxaliplatin, 5-FU | University of Erlangen-Nürnberg Medical School | Rectal Neoplasms | 12/15 | 06/16 | | |
NCT00769405 / 2006-006175-20: Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer |
|
|
| Completed | 3 | 264 | Europe | fluorouracil, leucovorin calcium, oxaliplatin, hyperthermia treatment | UNICANCER | Colorectal Cancer, Primary Peritoneal Cavity Cancer | 12/15 | | | |
NCT01786538: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines |
|
|
| Withdrawn | 3 | 0 | RoW | Regorafenib/FOLFOX, Placebo/FOLFOX | Asan Medical Center | Metastatic Colorectal Cancer | 05/16 | 05/17 | | |
NCT00068692: Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer |
|
|
| Completed | 3 | 225 | US | Radiotherapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, external radiation, Fluorouracil, Efudex, 5-FU, 5-Fluorouracil, Adrucil, Leucovorin Calcium, Leucovorin, Wellcovorin, citrovorun factor, folinic acid, LV, LCV, 5-formyl tetrahydrofolate, Oxaliplatin, 1-OHP, Dacplat, Eloxatin, Eloxatine, Trans-l-diaminocyclohexane oxalatoplatinum, Cis-[oxalato (trans-I-1 ,2-diaminocyclohexane) platinum(lI)], cis -[(1R,2R)-1,2-cyclohexanediamine- N,N'] [oxalate(2-)- 0,0'] platinum, Irinotecan, Camptosar, CPT-11, Camptothecin-11 | National Cancer Institute (NCI) | Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7 | 11/16 | 11/16 | | |
NCT01571284 / 2011-005724-17: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen |
|
|
| Completed | 3 | 781 | US, Canada, Europe, RoW | AFLIBERCEPT AVE0005, FOLFIRI | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 01/17 | 01/17 | | |
|
|
|
|
|
|
| Completed | 3 | 6088 | Europe | capecitabine, fluorouracil, oxaliplatin | Cancer Research UK, Glasgow | Colorectal Cancer | 11/17 | | | |
VISNU-1, NCT01640405 / 2012-000846-37: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells |
|
|
| Completed | 3 | 350 | Europe | modified FOLFOX6 + bevacizumab, FOLFOXIRI + Bevacizumab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Metastatic Colorectal Cancer | 11/18 | 11/18 | | |
FAST, NCT00735241: FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma |
|
|
| Withdrawn | 2/3 | 0 | US | SIR-Spheres microspheres, FOLFOX6 cycles 1-3, Eloxatin, Folinic acid, 5-FU, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards, Avastin | Sirtex Medical | Colorectal Carcinoma, Liver Metastases | 03/09 | 03/09 | | |
| Completed | 2/3 | 1814 | US, Canada, Europe, RoW | Cediranib, RECENTIN™, AZD2171, Bevacizumab, Avastin®, 5-fluorouracil ( in FOLFOX), 5-FU, Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX), Eloxatin® | AstraZeneca | Colorectal Cancer | 11/09 | 08/15 | | |
|
|
|
|
|
NCT00975897 / 2008-008323-15: Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer |
|
|
| Completed | 2/3 | 3240 | Europe | bevacizumab, cetuximab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, RNA analysis, cytogenetic analysis, fluorescence in situ hybridization, gene expression analysis, mutation analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, questionnaire administration, cognitive assessment | Medical Research Council | Colorectal Cancer | 08/10 | 12/12 | | |
NCT01550055: Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer |
|
|
| Completed | 2/3 | 512 | NA | CMAB009 plus Irinotecan, YiMaiLin for irinotecan, Irinotecan-only and sequential-CMAB009 | Shanghai Zhangjiang Biotechnology Limited Company, Shanghai Biomabs Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 12/12 | 07/15 | | |
BOS3, NCT01646554: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases |
|
|
| Withdrawn | 2/3 | 0 | NA | Modified FOLFOX6, 5-FU, folinic acid, oxaliplatin, Aflibercept, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Sanofi | Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer | 12/15 | 12/16 | | |
